Evidence map›Paper›PMID 35538491›Full record

ArticleJournal of translational medicine2022

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

Paolo A Ascierto, Allison Betof Warner, Christian Blank, Corrado Caracò, Sandra Demaria, Jeffrey E Gershenwald, Nikhil I Khushalani, Georgina V Long, Jason J Luke, Janice M Mehnert and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 6 countries.

Paolo A AsciertoDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.ORCID 0000-0002-8322-475X
Allison Betof WarnerMelanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christian BlankNetherlands Cancer Institute, Amsterdam, Netherlands.
Corrado CaracòDivision of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori "Fondazione Pascale" IRCCS, Naples, Italy.
Sandra DemariaDepartment of Radiation Oncology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Jeffrey E GershenwaldDepartment of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nikhil I KhushalaniH. Lee Moffitt Cancer Center (MCC) & Research Institute, Tampa, FL, USA.
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Jason J LukeUniversity of Pittsburgh Medical Center, UPMC) Hillman Cancer Center, Pittsburgh, PA, USA.
Janice M MehnertDepartment of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Caroline RobertInstitut de Cancérologie Gustave Roussy Et Université Paris-Saclay, Villejuif, France.
Piotr RutkowskiDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Hussein A TawbiMelanoma Medical Oncology, Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Brain Metastasis Clinic, UT MD Anderson Cancer Center, Houston, TX, USA.
Iman OsmanNew York University Langone Medical Center, New York, NY, USA.
Igor PuzanovDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITThe University of Texas MD Anderson Cancer Center · USCornell University · USDutch Cancer Society · NLMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNew York University · USNYU Langone Health · USRoswell Park Comprehensive Cancer Center · USThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe University of Sydney · AUUniversité Paris-Saclay · FRUPMC Hillman Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2-4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.

Indexed as

MelanomaCombined Modality TherapyCTLA-4 AntigenHumansImmunotherapyLymph Node ExcisionProtein Kinase InhibitorsCTLA-4 AntigenProtein Kinase InhibitorsAdjuvantAnti-CTLA-4Anti-PD-1BRAF inhibitorImmunotherapyLymphadenectomyMEK inhibitorMelanoma; stagingNeoadjuvantSurgeryTargeted therapy

Identifiers

PMID35538491
PMCPMC9087170
OpenAlexW4229452018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.